Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease
Murat Emre1, Patrizia Mecocci, Karina Stender
1Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. muratemre@superonline.com
Abstract:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, constituting the most common cause of dementia. Memantine, an N-methyl-D-aspartate receptor antagonist indicated for the treatment of moderate to severe AD, has been shown to provide benefits in cognitive, functional, and behavioral domains in large, randomized clinical trials. The current analysis combined data from six previously published studies and assessed the effect of memantine on various cognitive functions in 1826 patients (867 on placebo and 959 on memantine) with moderate to severe AD (MMSE<20). The Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and the Severe Impairment Battery (SIB) scores from all six studies were pooled and combined into three clusters representing discrete cognitive domains: language, memory, and praxis. At baseline, there were no clinically significant differences between the memantine- and placebo-treated groups. After 24 weeks, responder analyses revealed that memantine treatment resulted in statistically significantly more patients improving on each of the three clusters, language, memory, and praxis, compared with placebo, and a lower percentage of patients treated with memantine showed any worsening on any of the three clusters compared with patients receiving placebo. It is concluded that treatment with memantine provides benefits in all three cognitive functions.
Insights
Memantine treatment significantly improved language, memory, and praxis in patients with moderate to severe Alzheimer's disease (AD). This Alzheimer's drug demonstrated benefits across cognitive domains, showing more patients improved and fewer worsened compared to placebo.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive neurodegeneration.
- Memantine, an NMDA receptor antagonist, is approved for moderate to severe AD treatment.
- Previous trials indicate memantine's efficacy in cognitive, functional, and behavioral aspects.
Purpose of the Study:
- To assess the effect of memantine on cognitive functions in moderate to severe AD.
- To pool data from six studies to evaluate memantine's impact on language, memory, and praxis.
- To compare patient improvement and worsening across cognitive domains between memantine and placebo groups.
Main Methods:
- Meta-analysis of six published studies involving 1826 patients with moderate to severe AD (MMSE<20).
- Pooled data from Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and Severe Impairment Battery (SIB) scores.
- Cognitive functions clustered into language, memory, and praxis for analysis over 24 weeks.
Main Results:
- No significant baseline differences between memantine and placebo groups.
- Memantine treatment led to statistically significant improvements in language, memory, and praxis clusters after 24 weeks.
- Fewer patients on memantine showed worsening in any cognitive cluster compared to placebo.
Conclusions:
- Memantine treatment provides significant benefits for cognitive functions in moderate to severe Alzheimer's disease.
- The drug positively impacts language, memory, and praxis domains.
- Memantine demonstrates a favorable profile in slowing cognitive decline in AD patients.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...